Medtronic PLC $MDT Shares Sold by Park National Corp OH

Key Points

• Park National Corp OH trimmed its Medtronic stake by 18.4%, selling 21,343 shares and leaving it with 94,790 shares valued at about $9.11 million at the end of the quarter.
• EVP Harry Skip Kiil sold 52,524 shares for roughly $5.13 million, reducing his ownership by 61.58%; total insider ownership is about 0.26%.
• Medtronic beat quarterly estimates with $1.36 EPS (vs. $1.34) and $9.02B revenue (vs. $8.89B), set FY2026 guidance at $5.62–$5.66 EPS, and announced a $0.71 quarterly dividend (3.3% yield; ex-dividend Mar 27).

Park National Corp OH lessened its holdings in shares of Medtronic PLC (NYSE:MDT - Free Report) by 18.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 94,790 shares of the medical technology company's stock after selling 21,343 shares during the period. Park National Corp OH's holdings in Medtronic were worth $9,106,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in MDT. Delos Wealth Advisors LLC purchased a new position in Medtronic in the second quarter valued at approximately $27,000. Corundum Trust Company INC acquired a new position in shares of Medtronic in the 3rd quarter valued at $27,000. Valley Wealth Managers Inc. purchased a new position in shares of Medtronic in the 3rd quarter valued at $29,000. GoalVest Advisory LLC acquired a new stake in Medtronic during the 4th quarter worth $29,000. Finally, Imprint Wealth LLC purchased a new stake in Medtronic in the third quarter valued at $31,000. Hedge funds and other institutional investors own 82.06% of the company's stock.

Medtronic Price Performance

Medtronic stock opened at $86.83 on Friday. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87. The business has a 50 day simple moving average of $97.05 and a 200-day simple moving average of $96.71. Medtronic PLC has a 12 month low of $79.55 and a 12 month high of $106.33. The stock has a market capitalization of $111.48 billion, a PE ratio of 24.19, a price-to-earnings-growth ratio of 2.24 and a beta of 0.71.

Medtronic (NYSE:MDT - Get Free Report) last posted its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating analysts' consensus estimates of $1.34 by $0.02. The firm had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. Medtronic's quarterly revenue was up 5.8% on a year-over-year basis. During the same period last year, the firm posted $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts predict that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, April 17th. Stockholders of record on Friday, March 27th will be paid a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date is Friday, March 27th. Medtronic's payout ratio is 79.11%.

Wall Street Analyst Weigh In

A number of analysts have recently commented on MDT shares. Piper Sandler reiterated a "neutral" rating on shares of Medtronic in a research report on Monday, January 5th. CICC Research began coverage on Medtronic in a research report on Friday, January 30th. They set an "outperform" rating on the stock. William Blair raised Medtronic from a "market perform" rating to an "outperform" rating in a report on Tuesday, January 6th. Needham & Company LLC reaffirmed a "buy" rating and issued a $120.00 target price on shares of Medtronic in a report on Tuesday, March 10th. Finally, Wells Fargo & Company initiated coverage on shares of Medtronic in a research report on Friday, January 30th. They issued an "overweight" rating and a $114.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $110.74.

Insider Transactions at Medtronic

In related news, EVP Harry Skip Kiil sold 52,524 shares of the firm's stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the sale, the executive vice president owned 32,768 shares in the company, valued at $3,201,761.28. This trade represents a 61.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.26% of the stock is owned by corporate insiders.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.